Adam Elhofy
Chief Scientific Officer Cour Pharmaceuticals Development Co., Inc.
Dr. Elhofy has more than 25 years of scientific research experience in immunology, neuroscience, and oncology, with 20 scientific publications in peer-reviewed journals. Before joining COUR, Dr. Elhofy was the Chief Science Officer at Essential Pharmaceuticals, LLC, where he invented and patented the core technology for their Cell-Ess line of products, which can be used in a broad range of applications, including, but not limited to, bioproduction and primary research. He was also a Principal Investigator at a nanoparticle spin out from Argonne National Laboratories to treat skin-related autoimmune diseases. Dr. Elhofy was a Research Associate Professor at Northwestern Medical School, where he was funded with 2 multiple sclerosis training grants.
Seminars
- Presenting mechanism of action data from mouse models across COUR’s antigenspecific pipeline to show how their nanoparticle platform drives tolerance before a single patient is dosed, giving the field a reproducible template for validating mechanisms ahead of the clinic
- Pairing that mouse model functionality data with preclinical safety results to demonstrate that a blood-based biomarker readout can be functionally linked to disease-altering changes in the target tissue
- Setting out how this mechanistic and safety package informs indication and endpoint selection before trial design begins so the field can learn and avoid costly decisions
